Melanoma-associated antigen family (MAGE)

Melanoma cell antigens, also commonly known as melanoma-associated antigens (MAGE), represent a heterogeneous group of proteins that are overexpressed or specifically expressed by melanoma cells, making them critical targets for cancer immunotherapy. This category is subdivided into cancer-testis antigens (CTAs), such as the MAGE family and NY-ESO-1, which are typically restricted to germline tissues but aberrantly expressed in tumors, and melanocyte differentiation antigens like gp100, MART-1, and tyrosinase. These antigens are processed into peptides and presented on the cell surface via the Major Histocompatibility Complex (MHC), allowing them to be recognized by the immune system's T cells. Therapeutic strategies targeting these antigens include adoptive T-cell therapies, such as T-cell receptor (TCR) engineered T-cells, bispecific T-cell engagers, and cancer vaccines. For instance, afamitresgene autoleucel specifically targets MAGE-A4, while tebentafusp targets the gp100 peptide. While highly promising, targeting these antigens presents challenges such as on-target off-tumor toxicity—exemplified by vitiligo when targeting differentiation antigens present in normal melanocytes—and the potential for tumor escape through the downregulation of antigen expression or MHC molecules.

Other names

Melanoma cell antigensMelanoma-associated antigenMAGE familyCancer-testis antigensMelanoma-specific antigensMAGE proteins

Targeting of tumor-specific peptides presented on MHC molecules to induce T-cell mediated cytotoxicity and immune system activation